We propose a 5-year renewal of the University of Maryland Center of Excellence in Regulatory Science and Innovation (M-CERSI), a consortia of the two leading sister campuses within the University System of Maryland, and the Food and Drug Administration (FDA). M-CERSI leverages the biomedical and health outcomes strengths in Baltimore with the engineering and technologies strengths in College Park.
Aims i nclude: Establish core program infrastructure and management plan to ensure success; Conduct regulatory science research; and Provide regulatory science training/educational programs. Proposed research projects align with FDA high priority topics, develop and evaluate methods to improve quality and safety, and/or develop methods and tools to improve and streamline clinical and post-market evaluation. Research is collaborative with FDA scientists and employs a vast array of research capabilities at UM. Research is amplified by a robust training/educational program, which includes lectures, workshops, scholars program, and the America's Got Regulatory Science Talent Competition. The sum of these activities describe a vibrant, cutting edge Center that stimulates innovative thought, disseminates understanding of regulatory sciences and practices, and generates new knowledge in support of the FDA's fundamental mission ? to promote and protect the public health.

Agency
National Institute of Health (NIH)
Institute
Food and Drug Administration (FDA)
Type
Research Project--Cooperative Agreements (U01)
Project #
3U01FD005946-05S2
Application #
10324074
Study Section
Special Emphasis Panel (ZFD1)
Program Officer
Blumkemelor, Donna
Project Start
2016-09-15
Project End
2023-08-31
Budget Start
2020-09-01
Budget End
2021-08-31
Support Year
5
Fiscal Year
2021
Total Cost
Indirect Cost
Name
University of Maryland Baltimore
Department
Pharmacology
Type
Schools of Pharmacy
DUNS #
188435911
City
Baltimore
State
MD
Country
United States
Zip Code
21201
Guo, Dong; Yang, Hong; Li, Qing et al. (2018) Selective Inhibition on Organic Cation Transporters by Carvedilol Protects Mice from Cisplatin-Induced Nephrotoxicity. Pharm Res 35:204
Gaitonde, Priyanka; Bozzi, Laura M; Shaya, Fadia T (2018) Factors associated with use of disease modifying agents for rheumatoid arthritis in the National Hospital and Ambulatory Medical Care Survey. Semin Arthritis Rheum 47:649-653
Zhu, Peng; Ye, Zhi; Guo, Dong et al. (2018) Irinotecan Alters the Disposition of Morphine Via Inhibition of Organic Cation Transporter 1 (OCT1) and 2 (OCT2). Pharm Res 35:243
Deshpande, Tanvi M; Shi, Helen; Pietryka, John et al. (2018) Investigation of Polymer/Surfactant Interactions and Their Impact on Itraconazole Solubility and Precipitation Kinetics for Developing Spray-Dried Amorphous Solid Dispersions. Mol Pharm 15:962-974
Mackowiak, Bryan; Li, Linhao; Welch, Matthew A et al. (2017) Molecular Basis of Metabolism-Mediated Conversion of PK11195 from an Antagonist to an Agonist of the Constitutive Androstane Receptor. Mol Pharmacol 92:75-87
Oner, Z Gulsen; Michel, Sarah L J; Polli, James E (2017) Equivalence and regulatory approaches of nonbiological complex drug products across the United States, the European Union, and Turkey. Ann N Y Acad Sci 1407:26-38
Ali, Izna; Welch, Matthew A; Lu, Yang et al. (2017) Identification of novel MRP3 inhibitors based on computational models and validation using an in vitro membrane vesicle assay. Eur J Pharm Sci 103:52-59
Dong, Zhongqi; Ekins, Sean; Polli, James E (2015) Quantitative NTCP pharmacophore and lack of association between DILI and NTCP Inhibition. Eur J Pharm Sci 66:1-9
Dong, Zhongqi; Li, Qing; Guo, Dong et al. (2015) Synthesis and Evaluation of Bile Acid-Ribavirin Conjugates as Prodrugs to Target the Liver. J Pharm Sci 104:2864-76
Dong, Zhongqi; Ekins, Sean; Polli, James E (2015) A substrate pharmacophore for the human sodium taurocholate co-transporting polypeptide. Int J Pharm 478:88-95

Showing the most recent 10 out of 29 publications